Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Hemogenyx shares leap as it signs collaboration deal with major US biotechnology company

The biotech firm said the application of Hemogenyx's humanised mice as a tool for drug development and testing forms the basis of its collaboration with the US company
Biotech testing
It said the collaboration, which is expected to last between four to six months, is a continuation of work previously undertaken in partnership with the US company

HemoGenyx Pharmaceuticals PLC (LON:HEMO) shares jumped by over a quarter in value on Tuesday boosted by news the firm has entered into a collaboration with a major US biotechnology company in a deal worth up to approximately US$250,000 for the UK firm.

The biotechnology group said the collaboration follows on from the announcement made by the company on 26 February 2018, which confirmed the filing of a provisional patent application relating to its development of a new type of humanised mice with a chimeric mouse-human blood system.

READ: Hemogenyx shares soar after news of first solid data on leukaemia treatment

The firm added that this application of Hemogenyx's humanized mice as a tool for drug development and testing forms the basis of its collaboration with the unnamed US biotech company.

It said the collaboration, which is expected to last between four to six months, is a continuation of work previously undertaken in partnership with the company and has the potential to generate further income as the collaboration develops.

Dr Vladislav Sandler, Hemogenyx’s CEO & co-founder, commented:  The advancement of this collaboration and potential future collaborations serve both as a validation of our technology and a means of support for the further development of our CDX bi-specific antibody product candidate."

In early morning trading, Hemogenyx shares were up 25% at 3.88p.

 -- Adds share price --

View full HEMO profile View Profile

HemoGenyx Pharmaceuticals Timeline

Video
January 11 2018

Related Articles

Internet TV specialsit Falcon Media House transformed and ready to start generating revenues
August 25 2017
It has gone from a cash shell to fully fledged online TV company plugged into a massive market in a year and half
cannabis plant
February 01 2018
Today, the group closed the US$18mln acquisition of Citiva Medical and Citiva USA

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use